<DOC>
	<DOC>NCT01927341</DOC>
	<brief_summary>The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.</brief_summary>
	<brief_title>Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age ≥ 18 years Metastatic colorectal cancer Progression on or following standard therapy, or no standard therapy (phase Ib). Progression on or following at least 2prior fluoropyrimidinecontaining chemotherapy regimens (phase II) Written documentation of mutant or wildtype RAS Life expectancy ≥ 3 months ECOG performance status ≤ 2 Phase II arms 1 and 4 only: previous treatment with cetuximab, panitumumab, and/or other EGFR inhibitors Previous treatment with MEKinhibitors History of severe infusion reactions to monoclonal antibodies. Symptomatic or untreated leptomeningeal disease Symptomatic brain metastasis Current evidence of retinal disease; history of CSR, RVO or ophthalmopathy as assessed by ophthalmologic examination at baseline that would be considered a risk factor for CSR/RVO and history of keratitis. Acute or chronic pancreatitis Clinically significant cardiac disease Not adequate hematologic, renal and hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>MEK162,</keyword>
	<keyword>panitumumab,</keyword>
	<keyword>mutant RAS,</keyword>
	<keyword>wild-type RAS,</keyword>
	<keyword>metastatic colorectal cancer,</keyword>
	<keyword>adult mCRC patient</keyword>
</DOC>